Arcutis Biotherapeutics, Inc. 是一家生物制药公司,专注于开发和商业化皮肤病治疗方法。公司总部位于加利福尼亚州西湖村。
财务指标
营业收入
2026-09-30
$1.43亿
2026-06-30
$1.29亿
2026-03-31
$1.05亿
2025-12-31
$1.29亿
营业支出
2026-09-30
$1.22亿
2026-06-30
$1.02亿
2026-03-31
$1.04亿
2025-12-31
$9942.8万
净利润
2026-09-30
$880.1万
2026-06-30
$1500.9万
2026-03-31
-$1129.5万
2025-12-31
$1739.5万
净利润率
2026-09-30
6.11%
2026-06-30
11.55%
2026-03-31
-10.71%
2025-12-31
13.43%
每股收益
2026-09-30
$0.06
2026-06-30
$0.11
2026-03-31
$-0.09
2025-12-31
$0.13
息税折旧摊销前利润
2026-09-30
$1251.7万
2026-06-30
$1714.9万
2026-03-31
-$627.2万
2025-12-31
$2142.9万
有效税率
2026-09-30
2.16%
2026-06-30
0.89%
2026-03-31
-0.83%
2025-12-31
2.63%
项目
2026-09-30
2026-06-30
2026-03-31
2025-12-31
营业收入
$1.43亿
$1.29亿
$1.05亿
$1.29亿
营业支出
$1.22亿
$1.02亿
$1.04亿
$9942.8万
净利润
$880.1万
$1500.9万
-$1129.5万
$1739.5万
净利润率
6.11%
11.55%
-10.71%
13.43%
每股收益
$0.06
$0.11
$-0.09
$0.13
息税折旧摊销前利润
$1251.7万
$1714.9万
-$627.2万
$2142.9万
有效税率
2.16%
0.89%
-0.83%
2.63%
常见问题
ARQT is the ticker symbol for Arcutis Biotherapeutics, Inc., a biopharmaceutical company focused on developing and commercializing treatments for immune-mediated dermatological conditions. The stock represents ownership in this clinical-stage company, which is listed on the Nasdaq Global Market. Arcutis's pipeline includes topical therapies for plaque psoriasis, atopic dermatitis, and other skin diseases. Investors should note ARQT is a small-cap biotech stock, and its value is closely tied to clinical trial results and regulatory approvals.
Recent performance of ARQT stock can be found in the price chart and performance data displayed on this page. Stock performance for a biopharmaceutical company like Arcutis is often influenced by clinical trial readouts, regulatory decisions, and commercial uptake of approved products. For the latest price changes and percentage moves, refer to the live quote and historical returns section on this page.
Evaluating ARQT's valuation typically involves analyzing its market capitalization, cash position, and pipeline potential, as profitability may be limited. Biotech companies are often assessed using discounted cash flow models, comparable company analysis, or price-to-sales ratios rather than P/E. Since ARQT may not have positive earnings, traditional valuation metrics might not apply. For current valuation multiples and market cap, see the data provided on this stock page.
ARQT stock may be traded in pre-market and after-hours sessions on certain U.S. exchanges, depending on availability and your brokerage. These extended-hours trades occur outside the standard 9:30 AM to 4:00 PM Eastern Time window. However, liquidity can be lower and spreads wider, which may impact execution. Check with your broker for specific extended-hours trading policies for ARQT.
ARQT does not currently pay dividends. As a clinical-stage biopharmaceutical company, Arcutis Biotherapeutics focuses on funding research, development, and commercialization of its dermatology treatments rather than returning capital to shareholders through dividends. This is common among growth-oriented biotech firms. For the most up-to-date dividend information, refer to the dividend section on this page.
Key risks for ARQT include clinical trial failures, regulatory delays or rejections, and commercial challenges for its products. As a biotech, the company may face competition, intellectual property disputes, and the need for additional financing, which could dilute shareholders. Market sentiment and broader economic conditions can also affect ARQT's stock price. For a comprehensive risk profile, review the company's SEC filings and the risk factors disclosed in its annual report.